We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

DOJ Joins Qui Tam Suits Over Off-Label Natrecor Use

Law360 (February 19, 2009, 12:00 AM EST) -- The U.S. Department of Justice has decided to intervene in two qui tam suits alleging that Scios Inc. and its parent company, Johnson & Johnson, engaged in off-label marketing of the cardiac drug Natrecor.

The whistleblower suits, filed by former Scios sales managers in 2005 in the U.S. District Court for the Northern District of California, allege that the off-label marketing caused false and fraudulent claims to be submitted to federal health-care programs.

According to court records, the government elected to intervene on Feb. 11, but...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.